<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="349">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156606</url>
  </required_header>
  <id_info>
    <org_study_id>202100318</org_study_id>
    <nct_id>NCT05156606</nct_id>
  </id_info>
  <brief_title>Testosterone &amp; Tamoxifen Trial</brief_title>
  <acronym>T&amp;T</acronym>
  <official_title>T&amp;T Trial: Adding Testosterone to Tamoxifen in Male Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a concise single arm, feasibility study, which will be executed in the University&#xD;
      Medical Center Groningen, The Netherlands. Male patients with metastatic BC (n=6) are&#xD;
      eligible for this study after at least 1 line of conventional endocrine therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 3, 2022</start_date>
  <completion_date type="Anticipated">January 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Male patients with metastatic BC (n=6)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile</measure>
    <time_frame>At 8 weeks and follow-up through study completion, an average of 1 year</time_frame>
    <description>Safety profile, defined as the number of AEs and SAEs that occur while on tamoxifen and testosterone treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AR to ER ratio</measure>
    <time_frame>At baseline</time_frame>
    <description>AR to ER ratio on baseline FES- and FDHT-PET imaging (assessed per lesion and per patient by quantitative analysis using standardized uptake values (SUV)) and/or tumor tissue (assessed by percentage of ER and AR expression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Treatment response on 8 weeks FDG-PET/CT (assessed per lesion and per patient by quantitative analysis using standardized uptake values (SUV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging and response</measure>
    <time_frame>At 8 weeks and follow-up through study completion, an average of 1 year</time_frame>
    <description>Relation between baseline imaging and tumor characteristics to treatment response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events based on dosages</measure>
    <time_frame>At 8 weeks and follow-up through study completion, an average of 1 year</time_frame>
    <description>Difference in adverse events between the two testosterone dosages.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Male Breast Cancer</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel</intervention_name>
    <description>After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. A history of proven ER+ (&gt;10% of cells), AR+ (&gt;10% of cells), and HER2- metastatic BC&#xD;
&#xD;
          3. Tumor progression after at least one line of conventional endocrine therapy&#xD;
             (tamoxifen, AI, fulvestrant, CDK4/6, ±LHRH analogue).&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. Adequate hematological, renal and liver function as follows:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count &gt;100 x 109/L&#xD;
&#xD;
               -  White blood cell count &gt;3 x 109/L&#xD;
&#xD;
               -  AST and ALT &lt;2.5 or &lt;5.0 in case of liver metastases x upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  Creatinine clearance &gt;50mL/min&#xD;
&#xD;
               -  Prothrombin time, partial thromboplastin time and INR &lt;1.5 x ULN&#xD;
&#xD;
          6. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of prostate, testicular or liver cancer&#xD;
&#xD;
          2. Patients already using testosterone supplements&#xD;
&#xD;
          3. Patients using medication with anti-androgenic effects (e.g. spironolactone)&#xD;
&#xD;
          4. Elevated PSA (&gt;4μg/L) or severe urinary tract problems (as defined with a Prostate&#xD;
             Symptom Score &gt;19). Patients with known BRCA mutation and PSA &gt;3 μg/L will be referred&#xD;
             to the urologist for prostate cancer screening, and can participate if they have no&#xD;
             signs of prostate cancer.&#xD;
&#xD;
          5. Hematocrit &gt;50%&#xD;
&#xD;
          6. Patients with uncontrolled hypertension, diabetes mellitus or other significant&#xD;
             cardiovascular morbidity.&#xD;
&#xD;
          7. Patients with recent history of coronary artery disease or trombo-embolic events&#xD;
             within 6 months prior to screening&#xD;
&#xD;
          8. Severe concurrent disease, infection, co morbid condition that, in the judgment of the&#xD;
             investigator would make the patient inappropriate for enrollment&#xD;
&#xD;
          9. Visceral crisis and/or rapid progression necessitating chemotherapy&#xD;
&#xD;
         10. Previous allergic reaction to androgen agonists&#xD;
&#xD;
         11. Contra-indication for PET imaging&#xD;
&#xD;
         12. Tamoxifen or fulvestrant treatment &lt;5 weeks prior to FES-PET.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male breast cancer patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geke A.P. Hospers, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geke A.P Hospers, MD,PhD</last_name>
    <phone>+31503612821</phone>
    <email>g.a.p.hospers@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jasper J.L. van Geel, MD</last_name>
    <phone>+31503616161</phone>
    <email>j.j.l.van.geel@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Geke A.P. Hospers, MD,PhD</last_name>
      <phone>+31503612821</phone>
      <email>g.a.p.hospers@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jasper J.L. van Geel, MD</last_name>
      <phone>+31503616161</phone>
      <email>j.j.l.van.geel@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Geke A.P. Hospers, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Prof. Geke A.P. Hospers</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

